-2%
Semaglutide is a GLP-1 (glucagon-like peptide-1) analogue, with 94% similarity to human GLP-1. It works by:
- Stimulating insulin secretion and reducing glucagon release in a glucose-dependent manner, which helps lower blood sugar only when it is elevated.
- Slowing gastric emptying slightly, contributing to reduced post-meal glucose spikes.
- Suppressing appetite and reducing body fat, which aids in weight management.
Semaglutide does not impair glucagon secretion during hypoglycemia, maintaining safety in low blood sugar conditions.
For Type 2 Diabetes Mellitus (T2DM):
- As an adjunct to diet and exercise to improve blood glucose control in adults.
- To reduce the risk of major adverse cardiovascular events in adults with T2DM and established cardiovascular disease.
For Obesity or Overweight Adults:
- In combination with a reduced-calorie diet and increased physical activity for chronic weight management in:
- Adults with BMI ≥30 kg/m² (Obesity).
- Adults with BMI ≥27 kg/m² (Overweight) who also have at least one weight-related comorbidity (e.g., hypertension, T2DM, or dyslipidemia).